Sofosbuvir and daclatasvir

Hessel, Marleen H. M.; Cohen, Adam F.; Rißmann, Robert

doi:10.1111/bcp.13011

Cited by 9 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that currently, in the world, approximately 3% of the population (about 170 million people) has chronic hepatitis. 1,[2][3][4][5][6][7][8][9][10][11][12][13] The hepatitis C virus (HCV) is the etiological agent most related to the development of this disease. 2,[9][10][11][12][13][14][15][16][17] It is a 9,600 nucleotide, positive-sense, singlestranded, linear RNA virus whose genome is similar in organization to that of flaviviruses and pestiviruses.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of current treatments against hepatitis C virus

Zepeda

Murrieta

Contreras

et al. 2022

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

It is estimated that currently, in the world, approximately 3% of the population has chronic hepatitis, the hepatitis C virus is the etiological agent most related to the development of this pathology. The diversity of genotypes (7) and quasi-species of HCV, due to its high mutation rate, interferes with an effective humoral immunity. The aim of this work is precisely to evoke those usual drugs used in HCV therapy, as well as cutting-edge drugs. The goal of treatment is the eradication of HCV infection. One strategy offered by the WHO is to eradicate the virus in at-risk populations. Alternatives to the previously used treatment with interferon and ribavirin are shown in this paper; protease inhibitors and other targets have now been developed to make eradication of the virus more effective.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of current treatments against hepatitis C virus

Zepeda

Murrieta

Contreras

et al. 2022

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The goal of HCV treatment is to obtain a sustained virologic response (SVR), classically defined as undetectable HCV RNA 12 weeks or more following treatment completion [4] .…”

Section: Introductionmentioning

confidence: 99%

“…Oculomotor tests Smooth pursuit gain before and after treatment:Table(3)(4)(5)(6) did not show any statistically significant difference as regards Gaze evoked nystagmus, OPtokinetic nystagmus (gain), Saccade (accuracy and latency) & smooth pursuit testing before and after treatment.…”

mentioning

confidence: 95%

Vestibular & Balance Assessment in Hepatitis C Virus Patients Undergoing (Sovaldi/Daklinza) Regimen

Elhusseiny¹,

Shalaby²,

Taha³

et al. 2022

Egyptian Journal of Ear, Nose, Throat and Allied Sciences

View full text Add to dashboard Cite

Background: Previous Hepatitis C Virus (HCV) antiviral drugs reported to cause ototoxicity. Aim: To detect any possible adverse effects of Sovaldi/ Daklinza regimen related to vestibular & balance functions. Patients and Methods: Vestibular & balance were assessed in a total number of thirty adult HCV patients , ranging from twenty to sixty years old before administration of (Sovaldi/Daklinza) and three months later , using Vestibular office tests (Head shake test, Head thrust test, Fukuda stepping test& one leg stance). Videonystagmography (VNG), Sensory organization test (SOT) of Dynamic posturagraphy. Results: After treatment, all patients had normal vestibular office tests, normal VNG testing except for three patients (10% of the study sample) showed positional nystagmus after treatment that wasn't present before receiving Sovaldi/ Daclinza & normal balance function as demonstrated by SOT of Dynamic posturagraphy, with non-statistical significant difference when comparing before and after treatment findings. Conclusion: Sovaldi/Daklinza regimen used in HCV treatment has no statistically significant effect on vestibular & balance function.

show abstract

“…In July 2015, the FDA approved another DAA, i.e., Daclatasvir for use in combination with Sofosbuvir for the treatment of all HCV genotypes [9]. Although, DAAs are known to exhibit side effects such as fatigue, nausea, headache, and insomnia [10], the Sofosbuvir/ Daclatasvir combination therapy has not demonstrated any side effect in thalassemia major patients to the best of our knowledge. Here we are reporting the treatment of HCV genotype-1a infection by Sofosbuvir / Daclatasvir combination therapy in a child having thalassemia major.…”

Section: Introductionmentioning

confidence: 99%

Treatment of HCV Genotype-1a Infection with Sofosbuvir/ Daclatasvir in a Child Suffering from Thalassemia-Major

Mansoor¹,

Walayt²,

Ahmed

et al. 2021

RADS J. Pharm. Pharm. Sci.

View full text Add to dashboard Cite

Background: Beta thalassemia is the most common genetically transmitted disorder throughout the world. The life of a thalassemia patient depends on continuous blood transfusions, that can lead to various blood-borne viral infections mainly human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. Nevertheless, HCV infection is the most prevalent among blood transfusion-related blood-borne infections. Co-occurrence of thalassemia major with hepatic fibrosis,severe anemia, and iron over-load complicates HCV treatment. Additionally, treatment of HCV infection generally results in the manifestation of several drug-associated side effects, and the burden of continuous blood transfusions makes the condition worse. Aim: Efficacy and safety of Sofosbuvir/ Daclatasvir in a HCV infected child suffering from thalassemia major. Method: The patient was treated with direct-acting antiviral drugs including Sofosbuvir/ Daclatasvir for twenty weeks. The complete blood count (CBC) and Liver function test (LFT) data were obtained during the whole treatment. The efficacy and safety of treatment was evaluated by CBC and LFT values. The whole data was evaluated by Microsoft excel 2013. Result: No significant side effect was observed during the whole treatment. The hemoglobin (Hb) level remained normal and did not require additional blood transfusion. The end of therapy response (ETR) was achieved after twenty weeks of treatment. Conclusion: Sofosbuvir/ Daclatasvir were found effective in the thalassemia patient. There was no need for dose adjustment. The sustained viral response (SVR24) was achieved.

show abstract

Sofosbuvir and daclatasvir

Cited by 9 publications

References 8 publications

Efficacy of current treatments against hepatitis C virus

Efficacy of current treatments against hepatitis C virus

Vestibular & Balance Assessment in Hepatitis C Virus Patients Undergoing (Sovaldi/Daklinza) Regimen

Treatment of HCV Genotype-1a Infection with Sofosbuvir/ Daclatasvir in a Child Suffering from Thalassemia-Major

Contact Info

Product

Resources

About